Funding from industry disproportionately doesn't go into basic research, i.e. where the real innovation comes from. Looking at the paper you're referring to, the NIH in 2003 spent $14.8 billion in basic research versus $11 billion from industry.
More importantly, the numbers we're dealing pale in comparison to estimated savings from bargaining with the drug companies. The McKinsey Group has estimated a savings of $66 billion, which you'll notice is almost twice as large as the total pharmaceutical industry research in the paper. Assuming a drop-off in industry research funding proportional to the loss in revenues for the pharma industry (~10%), we could make that up many (somewhere between a factor of 20 and 60, depending on how much you want to emphasize the importance of basic research) times over with an increase in NIH funding from the savings.
BTW, to clarify things about the "lion's share," this survey includes medical device research under the category of industry research, which obviously isn't about drugs.
More importantly, the numbers we're dealing pale in comparison to estimated savings from bargaining with the drug companies. The McKinsey Group has estimated a savings of $66 billion, which you'll notice is almost twice as large as the total pharmaceutical industry research in the paper. Assuming a drop-off in industry research funding proportional to the loss in revenues for the pharma industry (~10%), we could make that up many (somewhere between a factor of 20 and 60, depending on how much you want to emphasize the importance of basic research) times over with an increase in NIH funding from the savings.
BTW, to clarify things about the "lion's share," this survey includes medical device research under the category of industry research, which obviously isn't about drugs.
Comment